Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) CEO William John Sibold sold 1,584 shares of the company's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $531,020.16. Following the sale, the chief executive officer now owns 54,303 shares in the company, valued at approximately $18,204,537.72. This trade represents a 2.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Madrigal Pharmaceuticals Stock Performance
Shares of MDGL stock traded down $17.22 during trading hours on Monday, hitting $310.92. The stock had a trading volume of 558,393 shares, compared to its average volume of 502,950. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The firm has a market capitalization of $6.78 billion, a PE ratio of -12.40 and a beta of -0.36. The stock's 50 day moving average is $314.37 and its 200 day moving average is $273.95. Madrigal Pharmaceuticals, Inc. has a twelve month low of $168.25 and a twelve month high of $368.29.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating analysts' consensus estimates of ($6.94) by $2.02. The business had revenue of $62.18 million during the quarter, compared to analyst estimates of $34.60 million. During the same quarter in the prior year, the firm posted ($5.34) earnings per share. As a group, research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.55 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of MDGL. Nisa Investment Advisors LLC increased its stake in Madrigal Pharmaceuticals by 47.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 68 shares during the period. Quest Partners LLC increased its stake in shares of Madrigal Pharmaceuticals by 172.8% during the third quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company's stock worth $123,000 after acquiring an additional 368 shares during the period. Centaurus Financial Inc. purchased a new position in Madrigal Pharmaceuticals during the second quarter worth about $163,000. Amalgamated Bank raised its holdings in Madrigal Pharmaceuticals by 20.2% during the second quarter. Amalgamated Bank now owns 607 shares of the biopharmaceutical company's stock worth $170,000 after purchasing an additional 102 shares in the last quarter. Finally, KBC Group NV lifted its position in Madrigal Pharmaceuticals by 73.5% in the fourth quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company's stock valued at $188,000 after purchasing an additional 258 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on MDGL shares. UBS Group upped their target price on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Cantor Fitzgerald reissued a "neutral" rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. JMP Securities reaffirmed a "market outperform" rating and set a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Friday, January 10th. StockNews.com raised Madrigal Pharmaceuticals to a "sell" rating in a report on Saturday, October 12th. Finally, HC Wainwright raised their price target on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a "buy" rating in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $351.67.
View Our Latest Analysis on MDGL
About Madrigal Pharmaceuticals
(
Get Free Report)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Madrigal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Madrigal Pharmaceuticals wasn't on the list.
While Madrigal Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
